Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor.

Trial Profile

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Antithymocyte globulin; Fludarabine; Melphalan
  • Indications Advanced breast cancer; Ovarian cancer; Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2011 Planned end date changed from 1 Feb 2012 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 03 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top